News | August 08, 2024
Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
This transaction is the third acquisition by three different Japanese players in this segment
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Himanshu brings with him a wealth of rich experience from commercial, marketing, and general management roles
The Issue opened on June 18, 2024 and closed on June 21, 2024
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
This strategic decision will unlock significant value for our scientific and industrial products business
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Subscribe To Our Newsletter & Stay Updated
